Thomas Warner

University College London
Country flagUnited Kingdom
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Dementia in Lewy body diseases (LBD) is common and arises through heterogeneous and incompletely understood pathways. Evidence suggests contributions from genetic factors, including APOE ε4 genotype, co-pathology including concomitant Alzheimer’s disease pathology and hypoperfusion related to orthostatic hypotension. However, the relative impact of these factors remains unclear. To address this, we analysed 399 post-mortem brains from LBD cases comprising Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies, and controls, integrating APOE genotype, clinical data and assessment of ischaemic pathology alongside large-scale digital pathology quantification. We established an image analysis pipeline utilising machine learning to enable automated, standardised measurement of α-synuclein, amyloid-β, and phosphorylated tau burden across multiple brain regions. Quantitative pathology strongly correlated with semi-quantitative ratings and outperformed conventional staging in predicting dementia. Across multiple analytical approaches, APOE ε3 and ε4 carriers showed distinct dementia risk profiles. APOE ε3 carriers developed dementia at lower quantitative α-synuclein and amyloid-β thresholds than ε4 carriers, although overall dementia risk was dominated by ε4 genotype, consistent with ε4 both promoting greater pathology accumulation and modifying the threshold for dementia onset. Orthostatic hypotension and ischaemic pathology increased dementia risk only in ε3 carriers with low Lewy and Alzheimer’s proteinopathy burden, while male sex further modulated dementia risk for this subgroup. A data-driven progression model (SuStaIn) identified four trajectories of Lewy pathology: two corresponding to recognised patterns, one brainstem-first and the other with early amygdala involvement, and two representing novel cortical-onset patterns, one with early cingulate cortex involvement and the other starting in neocortex before limbic and brainstem involvement. Co-pathology progression modelling identified subtypes with early predominance of amyloid-β, phosphorylated tau, or α-synuclein, and showed that Lewy subtypes follow two propagation trajectories in opposite directions. Together, these findings demonstrate that integrating quantitative pathology with genotype and clinical data uncovers distinct yet overlapping pathways to dementia in LBD, refining disease progression models and providing a basis for genotype- and pathology-informed patient stratification in therapeutic trials.

Year:

2025

Progressive supranuclear palsy (PSP) is a heterogeneous neurodegenerative disease characterised by the accumulation of misfolded 4-repeat tau within neurones and glial cells. There is limited longitudinal data on pathologically confirmed PSP patients with phenotypes other than classical Richardson’s syndrome (RS), and the pathomechanisms responsible for the broad variability in clinical phenotype and progression are not well understood. An unresolved question in this context is whether distinct spatiotemporal patterns of tau pathology propagation exist within the clinicopathological spectrum of PSP. We identified 241 consecutive, pathologically confirmed patients with PSP from the Queen Square Brain Bank for Neurological Disorders (2010-2022). Phenotyping was performed based on clinical features present within the first 3 years from symptom onset according to the Movement Disorder Society (MDS) criteria, and specific clinical features and disease milestones were recorded. Genotyping was performed using Illumina NeuroBooster and NeuroChip arrays and MAPT haplotype, APOE genotype, TRIM11 rs564309, and SLC2A13 rs2242367 single nucleotide polymorphism status were collated from imputed data. Tissue sections from eight brain regions, mounted on glass slides, were immunostained for hyperphosphorylated tau and digitised using whole-slide scanning. Forty-one anatomical regions of interest were manually segmented, and total tau pathology burden was quantified using an automated, machine learning-based algorithm. The associations between survival and both clinicogenetic features and regional tau pathology burden were modelled using Cox regression and generalised linear models, respectively, and the Subtype and Stage Inference (SuStaIn) algorithm was used to identify subgroups with distinct progression patterns. We have identified: 1) several clinical predictors of survival in PSP and the relationship between regional tau pathology burden and survival; 2) novel anatomical reference standards for the expected distribution of tau pathology across MDS-defined PSP phenotypes, emphasising region-specific white matter involvement in patients with corticobasal syndrome and speech/language variants; 3) associations linking biological sex, MAPT haplotype, and TDP-43 co-pathology to clinical phenotype and regional tau pathology burden; 4) patterns of covariance in regional tau pathology implicating inter-regional connectivity in tau spreading; and 5) three distinct spatiotemporal patterns of tau pathology progression: one characterised by initial involvement of subcortical grey matter followed by rostral spread to frontal white matter and other cortical regions, and two characterised by early, simultaneous involvement of subcortical grey matter and frontal white matter. Taken together, these results indicate that PSP clinicopathological heterogeneity is mediated by propagation of tau pathology along anatomically connected networks, and via cell- autonomous mechanisms influenced by sex, genetic factors and possibly co-pathology.

Year:

2025

Background Several neurodegenerative diseases can mimic the clinical presentation of progressive supranuclear palsy (PSP), limiting accurate diagnosis during life. This has important implications for clinical practice, biomarker studies, and therapeutic trial design. Objectives To investigate whether the proportion of clinically diagnosed PSP patients with non‐PSP pathology (termed ‘mimics’) has changed over the past 20 years since last examined in this cohort, and to identify clinical features that distinguish confirmed PSP from these mimics. Methods We reviewed the clinical records of pathologically confirmed PSP patients donated to the Queen Square Brain Bank from 2010 to 2022, and PSP mimics donated from 1989 to 2022. Demographic information, clinical features, and progression milestones were recorded. Results We included 236 pathologically confirmed PSP patients and 72 mimics. The main pathologies in PSP mimics were Lewy body disease (30.5%), corticobasal degeneration (23.6%), and multiple system atrophy (18.1%). A final clinical diagnosis of PSP between 2010 and 2022 had a positive predictive value of 86% for underlying PSP pathology and a false negative rate of 17%. Clinical features present in the first 3 years that favoured non‐PSP pathology in this cohort include levodopa responsiveness, orthostatic hypotension, dysarthria, and a subcortical phenotype. Conclusions Clinical diagnosis of PSP has improved since last examined in this cohort 20 years ago. Although certain clinical features may point to non‐PSP pathologies, a proportion of patients are difficult to distinguish on clinical grounds alone. This should be reflected in clinical trial design, and further studies will be required to determine the utility of emerging biomarkers in this setting. © 2025 International Parkinson and Movement Disorder Society.

Year:

2025

Background Alpha-synuclein seed amplification assay (a-syn SAA) has been proposed to be a diagnostic biomarker for Parkinson’s disease (PD). Here, we have explored the diagnostic and prognostic value of cerebrospinal fluid (CSF) a-syn SAA status and seeding kinetics in PD. Methods Baseline CSF a-syn SAA data and longitudinal clinical data were collected and analysed between 1 st January 2010 and 1 st April 2022 for the Parkinson’s Progression Markers Initiative (PPMI) and UK parkinsonism cohorts respectively. We calculated the sensitivity and specificity of a-syn SAA in PD and controls, used linear regression to analyse a-syn SAA positive vs. negative group comparisons, and used time-to-event analyses to assess the ability of a-syn SAA seeding kinetic measures to predict clinical decline in PD. Findings We studied 1,402 participants: publicly available data from the PPMI cohort, n=1275 (PD, n=1,036; controls, n=239); newly generated data from the UK parkinsonism cohort, n=127 (PD, n=66; progressive supranuclear palsy (PSP), n=52; controls n=9). Over 2-5 years of follow-up, the sensitivity of a-syn SAA in PD was 87.7% and the specificity in controls was 91.9%. A-syn SAA was positive in 8/52 (15.4%) PSP samples with distinct ‘low and slow’ kinetics. A-syn SAA negative LRRK2-PD participants (n=57) had an older mean (SD) age at symptom onset (63.0 (7.6) vs. 55.4 (9.9) years) and higher mean (SD) baseline serum neurofilament light chain levels (20.4 (13.2) vs. 13.8 (8.6) pg/ml), p<0.05, vs. a-syn SAA positive LRRK2-PD participants (n=110). The baseline seeding kinetic measure, time to threshold, predicted cognitive decline in PD, defined as MoCA ≤21 (HR 2.51, 95% CI 1.50-4.20, p=0.001). Interpretation In PD, a-syn SAA may have value as a diagnostic and prognostic biomarker in clinical practice and as a stratification tool in clinical trials. Furthermore, we have highlighted the presence of pathological heterogeneity in LRRK2-PD. Funding Medical Research Council, PSP Association.

Year:

2024

Background Seed amplification assay (SAA) testing has been developed as a biomarker for the diagnosis of α‐synuclein‐related neurodegenerative disorders. Objective The objective of this study was to assess the rate of α‐synuclein SAA positivity in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) and to analyze clinical and pathological features of SAA‐positive and ‐negative cases. Methods A total of 96 cerebrospinal fluid samples from clinically diagnosed PSP (n = 59) and CBS (n = 37) cases were analyzed using α‐synuclein SAA. Results Six of 59 (10.2%) PSP cases were α‐synuclein SAA positive, including one case who was MSA‐type positive. An exploratory analysis showed that PSP cases who were Parkinson's disease–type positive were older and had a shorter disease duration compared with SAA‐negative cases. In contrast, 11 of 37 (29.7%) CBS cases were α‐synuclein SAA positive, including two cases who were MSA‐type positive. Conclusions Our results suggest that α‐synuclein seeds can be detected in PSP and CBS using a cerebrospinal fluid α‐synuclein SAA, and in PSP this may impact on clinical course.

Year:

2024

Abnormal α-synuclein (αSyn), including an oligomeric form of αSyn, accumulates and causes neuronal dysfunction in the brains of patients with multiple system atrophy. Neuroprotective drugs that target abnormal αSyn aggregation have not been developed for the treatment of multiple system atrophy. In addition, treating diseases at an early stage is crucial to halting the progress of neuronal damage in neurodegeneration. In this study, using early-stage multiple system atrophy mouse model and in vitro kinetic analysis, we investigated how intranasal and oral administration of trehalose can improve multiple system atrophy pathology and clinical symptoms. The multiple system atrophy model showed memory impairment at least four weeks after αSyn induction. Behavioural and physiological analyses showed that intranasal and oral administration of trehalose reversed memory impairments to near-normal levels. Notably, trehalose treatment reduced the amount of toxic αSyn and increased the aggregated form of αSyn in the multiple system atrophy model brain. In vitro kinetic analysis confirmed that trehalose accelerated the aggregate formation of αSyn. Based on our findings, we propose a novel strategy whereby accelerated αSyn aggregate formation leads to reduced exposure to toxic αSyn oligomers, particularly during the early phase of disease progression.

Year:

2024

RNA editing is a post transcriptional mechanism that targets changes in RNA transcripts to modulate innate immune responses. We report the role of astrocyte specific, ADAR1 mediated RNA editing in neuroinflammation in Parkinson’s disease. We generated hiPSC-derived astrocytes, neurons and co-cultures and exposed them to small soluble alpha-synuclein aggregates. Oligomeric alpha-synuclein triggered an inflammatory glial state associated with TLR activation, viral responses, and cytokine secretion. This reactive state resulted in loss of neurosupportive functions, and the induction of neuronal toxicity. Notably, interferon response pathways were activated leading to upregulation, and isoform switching of the RNA deaminase enzyme, ADAR1. ADAR1 mediates A-to-I RNA editing, and increases in RNA editing were observed in inflammatory pathways in cells, as well as in post-mortem human PD brain. Aberrant, or dysregulated, ADAR1 responses and RNA editing may lead to sustained inflammatory reactive states in astrocytes triggered by alpha-synuclein aggregation, and this may drive the neuroinflammatory cascade in Parkinson’s.

Year:

2024

Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by neuronal loss and gliosis, with oligodendroglial cytoplasmic inclusions (GCI’s) containing α-synuclein being the primary pathological hallmark. Clinical presentations of MSA overlap with other parkinsonian disorders such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP), posing challenges in early diagnosis. Numerous studies have reported perturbations in DNA methylation in neurodegenerative diseases, with candidate loci being identified in various parkinsonian disorders including MSA, PD, and PSP. Although MSA and PSP present with substantial white matter pathology, alterations in white matter have also been reported in PD. However, studies comparing the DNA methylation architectures of white matter in these diseases are lacking. We therefore aimed to investigate three parkinsonian diseases, MSA, PD, and PSP, to identify shared and disease-specific DNA methylation alterations in white matter. Genome-wide DNA methylation profiling of frontal lobe white matter of individuals with MSA (n=17), PD (n=17), and PSP (n=16) and controls (n=15), using the Illumina EPIC array, revealed substantial commonalities in DNA methylation perturbations in MSA, PD, and PSP. We further used weighted gene correlation network analysis to identify disease-associated co-methylation signatures and identified dysregulation in processes relating to Wnt signalling, signal transduction, endoplasmic reticulum stress, mitochondrial processes, RNA interference, and endosomal transport. Our results highlight several shared DNA methylation perturbations and pathways indicative of converging molecular mechanisms contributing towards neurodegeneration in the white matter of all three parkinsonian diseases.

Year:

2024

Collaborators (17)

Olga Kopach

Lecturer

City St George's University

UNITED KINGDOM
View details

Zhongbo Chen

The Francis Crick Institute

UNITED KINGDOM
View details

Yau Mun Lim

University College London

UNITED KINGDOM
View details

Regina Reynolds

University College London

UNITED KINGDOM
View details

Mina Ryten

University College London

UNITED KINGDOM
View details

Dmitri Rusakov

Professor of Neuroscience

University College London

UNITED KINGDOM
View details

James B. Rowe

Associate Director

-

UNITED KINGDOM
View details

Kailash Bhatia

Professor of Clinical neurology

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Raquel Real

University College London

UNITED KINGDOM
View details

Sebastian Brandner

University College London

UNITED KINGDOM
View details

David Klenerman

University of Cambridge

UNITED KINGDOM
View details

Emil Gustavsson

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Jonathan Mill

Professor

University of Exeter

UNITED KINGDOM
View details

Conceição Bettencourt

University College London

UNITED KINGDOM
View details

Huw Morris

University College London

UNITED KINGDOM
View details

Zane Jaunmuktane

Clinical Lecturer and Honorary Consultant Neuropathologist

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Christopher Kobylecki

-

UNITED KINGDOM
View details